Functional Precision Medicine by Design

Targeted therapies do not work for everyone

Single Drug Therapies
20%
Targeted Therapies
25-75%
Immunotherapies
20-40%

Every 4 week delay in cancer treatment causes up to 28% increase in mortality risk.

Murumägi, A., Ungureanu, D., Khan, S. et al. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer. Br J Cancer 128, 678–690 (2023).​

It's all possible now
through Nine Diagnostics.

A faster path to the most effective treatment with better outcomes

We develop holistic profiles based on a patient’s personal health data, demographics, social determinants of health, and other relevant factors pertinent to the ultimate outcomes.
Multidimensional datasets are acquired from fluorescent emissions using an array of nanoscale sensing elements that detect health abnormalities and signals of treatment effectiveness in small patient samples.​
Get patients the most effective treatment faster by providing feedback to select and optimize treatment faster.
Researchers and drug developers can now understand new biology with biomarkers that react dynamically, in real time, directly from patients.
Clinicians can accelerate validation of precision medical treatments in real patient situations.
Patients ultimately get the most effective treatment as soon as possible.

Shorter closed feedback loops save lives

June 25, 2026
Nine Diagnostics Joins Damon Runyon Cancer Research Foundation InVEST Program
Nine Diagnostics Joins Damon Runyon InVEST Program
Nine Diagnostics has been selected for the Damon Runyon Cancer Research Foundation Innovative Ventures in Early-Stage Technologies (InVEST) program, which provides a $50,000 SAFE investment to companies founded by Damon…
Read More
May 14, 2026
Freddy Nguyen Featured on Pitt HexAI Podcast for Precision Medicine Innovation
Freddy Nguyen featured on Pitt HexAI podcast for precision medicine diagnostics
Nine Diagnostics CEO and Co-Founder Freddy T. Nguyen, MD, PhD, appeared on Episode 40 of the Pitt HexAI Podcast to discuss AI-enabled cancer diagnostics and the entrepreneurship pathway behind Nine…
Read More
May 13, 2026
Freddy Nguyen Featured on From Models to Medicine for Diagnostic AI Equity
Freddy Nguyen featured on From Models to Medicine podcast for diagnostics innovation
Nine Diagnostics CEO and Co-Founder Freddy T. Nguyen, MD, PhD, joined KAMI Think Tank’s From Models to Medicine podcast for Episode 8, “The Equity Gap in Diagnostic AI,” a candid…
Read More
March 31, 2026
Nine Diagnostics Joins DRIVE Accelerator with SCbio and MassBio
Nine Diagnostics Joins DRIVE Accelerator with SCbio and MassBio
Nine Diagnostics is participating in the Spring 2026 DRIVE Accelerator Biomarkers and Diagnostics track, a national program run by SCbio in partnership with MassBio supporting early-stage companies advancing next-generation diagnostic…
Read More
March 25, 2026
Nine Diagnostics Pitches at BioTools Innovator East Coast Road Tour
Freddy T. Nguyen presenting at the BioTools Innovator East Coast Road Tour pitch event
Nine Diagnostics participated in the BioTools Innovator East Coast Road Tour pitch event, a competitive selection process run by BioTools Innovator, the first accelerator focused exclusively on life science tools…
Read More
March 17, 2026
Industrial Adoption of Carbon Nanotubes — Nano Letters
Nine Diagnostics Industrial Adoption of Carbon Nanotubes - Nano Letters
Nine Diagnostics co-founders Daniel A. Heller, PhD, and Mijin Kim, PhD, co-authored a perspective in Nano Letters reviewing the current landscape and outlook for the industrial integration of carbon nanotubes…
Read More
February 9, 2026
Nine Diagnostics Selected to Present at FNIH Biomarkers Consortium 20th Anniversary Symposium
Nine Diagnostics Selected to Present at FNIH Biomarkers Symposium
Nine Diagnostics was selected to present at the FNIH Biomarkers Consortium 20th Anniversary Symposium, a leading forum convening senior leaders across academia, industry, and government to advance biomarker science. The…
Read More
January 20, 2026
Freddy Nguyen Featured in The Scientist on NSF Tech Labs Initiative
Freddy T. Nguyen, MD, PhD featured in The Scientist on NSF Tech Labs Initiative
Nine Diagnostics CEO and co-founder Freddy T. Nguyen, MD, PhD, was featured in The Scientist in an article by Laura Tran, PhD, gathering researcher and entrepreneur responses to the National…
Read More
January 20, 2026
Heller and Kim Selected for ARPA-H LIGHT Program on Lymphatic Disease Diagnostics
Heller and Kim Selected for ARPA-H LIGHT Program LANTERN - Lymphatic Disease Diagnostics
Nine Diagnostics co-founders Daniel Heller and Mijin Kim are contributing to the ARPA-H LIGHT program as part of the Weill Cornell Medicine-led LANTERN team, one of 11 groups funded through…
Read More
January 16, 2026
Nine Diagnostics and Orbits Oncology Launch Exploratory Partnership on Precision Oncology Platform
Nine Diagnostics and Orbits Oncology exploratory partnership, with headline framing the collaboration as early-stage precision oncology exploration
Nine Diagnostics and Orbits Oncology have entered into an exploratory partnership to jointly develop a next-generation precision oncology diagnostics platform. The collaboration pairs Nine Diagnostics' nanosensor-based molecular fingerprinting, which captures…
Read More
December 24, 2025
Nanosensor Liquid Biopsy Detects and Classifies Brain Tumors — Nature Nanotechnology
Nine Diagnostics Nanosensor Liquid Biopsy Detects and Classifies Brain Tumors - Nature Nanotechnology
Nine Diagnostics co-founders Daniel A. Heller, PhD, and Mijin Kim, PhD, co-authored a cover article in Nature Nanotechnology (February 2026) demonstrating 98% accuracy in brain tumor detection and 71% accuracy…
Read More
October 30, 2025
Nine Diagnostics Graduates from ACS BrightEdge Entrepreneurs Program
ACS BrightEdge Graduates card, rebuilt from original photo, larger people, all four names white and uniform
Nine Diagnostics graduated from the American Cancer Society BrightEdge Entrepreneurs Program, culminating in a Demo Day pitch presentation of the Nine Diagnostics nanosensor-enabled, machine learning-driven diagnostic platform. The 10-month program,…
Read More
October 3, 2025
Daniel Heller Featured on KVIA-TV ABC-7 for Nanosensor Ovarian Cancer Detection Research
Daniel Heller featured on KVIA-TV ABC-7 for nanosensor ovarian cancer detection
Nine Diagnostics co-founder Daniel A. Heller, PhD, was featured on KVIA-TV ABC-7 News El Paso in October 2025 for his work developing a nanosensor-based liquid biopsy for early ovarian cancer…
Read More
September 22, 2025
Nine Diagnostics Selected for Medical Alley Q3 Innovation Showcase
Nine Diagnostics selected for Medical Alley Innovation Showcase
Nine Diagnostics presented at the Q3 Medical Alley Innovation Showcase on September 22, 2025, one of six companies selected to present within Minnesota's health innovation ecosystem, one of the most…
Read More
September 18, 2025
Nine Diagnostics Selected for Second Annual Boston Biotech Investor Day
Nine Diagnostics Selected for Second Annual Boston Biotech Investor Day
Nine Diagnostics was selected to present at the second annual Boston Biotech Investor Day, an invitation-only Seaport event co-hosted by LabCentral, BioLabs, The Engine, and the Termeer Institute, bringing together…
Read More
September 17, 2025
Nine Diagnostics Wins Runner-Up at RESI Boston Longevity Competition
Nine Diagnostics wins runner-up at RESI Boston Longevity track
Nine Diagnostics placed second in the Longevity Global Pitch Competition at RESI Boston on September 17, 2025, part of a newly launched longevity and aging track organized by Life Science…
Read More
August 28, 2025
Nine Diagnostics Co-Founder Daniel Heller in Women’s Health Magazine
Daniel Heller featured in Women's Health magazine for nanosensor cancer research
Nine Diagnostics co-founder Dr. Daniel Heller was featured in Women's Health Magazine discussing why ovarian cancer remains so difficult to detect early and how AI-enabled nanosensor technology is changing that…
Read More
August 3, 2025
Building a Measurement Science Startup — Applied Spectroscopy Practica
Applied Spectroscopy Practica - Building a Measurement Science Startup
Freddy T. Nguyen, MD, PhD, CEO and Co-Founder of Nine Diagnostics, co-authored a paper in Applied Spectroscopy Practica presenting a framework for translating measurement science into healthcare products, drawn from…
Read More
May 22, 2025
Nine Diagnostics CEO Freddy Nguyen Named 2025 National Academy of Medicine Scholar in Diagnostics
Nine Diagnostics CEO Freddy Nguyen Named 2025 NAM Scholar
Nine Diagnostics co-founder and CEO Dr. Freddy T. Nguyen has been named a 2025 Scholar in Diagnostic Excellence by the National Academy of Medicine, recognizing leaders advancing diagnostic quality, safety,…
Read More
May 18, 2025
Nine Diagnostics CEO Freddy Nguyen at MIT Health Science Forum 2025
Nine Diagnostics CEO Freddy Nguyen selected to present at MIT Health Science Forum 2025
Nine Diagnostics CEO Dr. Freddy Nguyen delivered an MIT Startup Exchange Lightning Talk at the 2025 MIT Health Science Forum, hosted by the MIT Industrial Liaison Program, an event convening…
Read More
April 14, 2025
The Definitive Reference on Carbon Nanotubes in Biomedicine — Handbook of Carbon Nanomaterials
Handbook of Carbon Nanomaterials - The Definitive Reference on Carbon Nanotubes in Biomedicine
Nine Diagnostics co-founders Daniel A. Heller, PhD, and Mijin Kim, PhD, co-edited a two-volume reference work on carbon nanomaterials in biomedicine, published by World Scientific in 2025 as part of…
Read More
February 12, 2025
Nine Diagnostics Joins ACS BrightEdge Entrepreneurs Program
Nine Diagnostics Joins ACS BrightEdge Entrepreneurs Program
Nine Diagnostics was selected to join the American Cancer Society's BrightEdge Entrepreneurs Program, a competitive initiative supporting oncology startups with high-impact potential through top-tier mentorship, investment opportunities, and strategic connections…
Read More
December 20, 2024
Nine Diagnostics Co-Founder Daniel Heller Featured in BBC News
Daniel Heller featured in BBC News for nanosensor cancer detection research
Nine Diagnostics co-founder Dr. Daniel Heller was featured in BBC News as part of its “AI Breakthroughs” series, discussing how AI and nanotechnology could transform detection of ovarian and other…
Read More
December 6, 2024
Nine Diagnostics Joins U.S.-Dutch Consortium for Women’s Health Diagnostics
Nine Diagnostics Joins U.S.-Dutch Consortium for Women's Health Diagnostics - Building a Dutch-US Consortium for Gynecological Health
Nine Diagnostics joined a U.S.-Dutch consortium to co-produce a white paper on advancing diagnostic tools and treatments for gynecological cancers, serving as the molecular diagnostics partner with its AI-enabled multiomics…
Read More
November 14, 2024
Nine Diagnostics Selected for Merck Digital Sciences Studio Cohort 3
Nine Diagnostics Selected for Merck Digital Sciences Studio Cohort 3
Nine Diagnostics was accepted into Merck Digital Sciences Studio Cohort 3, a 10-month digital accelerator providing direct investment, strategic mentorship, and industry connections to early-stage biomedical startups advancing AI and…
Read More
October 6, 2024
Nine Diagnostics Selected for Inaugural CancerHackerLab Accelerator Cohort
Nine Diagnostics Selected for Inaugural CancerHackerLab Accelerator Cohort
Nine Diagnostics was selected for the inaugural cohort of the CancerHackerLab Accelerator, a cancer-focused innovation program connecting early-stage oncology companies with clinical mentors, biopharma advisors, patient advocates, and a peer…
Read More
September 19, 2024
Nine Diagnostics Wins Novo Nordisk Golden Ticket for LabCentral Residency
Nine Diagnostics wins Novo Nordisk Golden Ticket award
Nine Diagnostics was selected as one of two recipients of the 2024 Novo Nordisk Golden Ticket, a competitive award run jointly by Novo Nordisk’s Bio Innovation Hub and LabCentral recognizing…
Read More
September 13, 2024
Nine Diagnostics Selected to Participate in The Engine’s Blueprint Program
Nine Diagnostics Selected for The Engine Blueprint Program
Nine Diagnostics was selected to participate in The Engine's Blueprint program, a competitive early-stage cohort for tough tech companies co-founded by MIT, with participation beginning September 13, 2024. The program…
Read More
July 17, 2024
Nine Diagnostics Selected to Participate in NSF I-Corps Program at MIT
Nine Diagnostics Selected for NSF I-Corps Program at MIT
Nine Diagnostics was selected to participate in the NSF I-Corps Program at MIT, a structured customer discovery program administered through the New England Regional Innovation Node at MIT, with participation…
Read More
March 8, 2024
Nine Diagnostics Founded to Advance AI-Enabled Nanosensor Diagnostics
Nine Diagnostics Founded card, Recognition Purple, 50:50 panel split
Nine Diagnostics was incorporated on March 8, 2024, bringing together Freddy T. Nguyen, MD, PhD, Daniel A. Heller, PhD, and Mijin Kim, PhD to build an AI-enabled multi-omic nanosensor platform…
Read More
February 15, 2024
Daniel Heller Featured on NBC New York for AI-Enabled Ovarian Cancer Blood Test Research
Daniel Heller featured on NBC New York for AI-enabled ovarian cancer detection
Daniel A. Heller, PhD, lead researcher in the Cancer Nanomedicine Lab at Memorial Sloan Kettering Cancer Center, was featured on NBC New York (WNBC-TV 4) in February 2024 for his…
Read More
October 17, 2023
Mijin Kim Named a 2023 STAT Wunderkind for Nanosensor Cancer Detection Research
Mijin Kim named 2023 STAT Wunderkind, Memorial Sloan Kettering Cancer Center
Mijin Kim, PhD, a postdoctoral researcher in the Heller Lab at Memorial Sloan Kettering Cancer Center, was named a 2023 STAT Wunderkind, an annual honor recognizing 28 early-career researchers across…
Read More
June 29, 2022
Mijin Kim Named a 2022 MIT Technology Review Innovator Under 35
Mijin Kim named MIT Technology Review Innovators Under 35 2022 for nanosensor cancer detection
Mijin Kim, PhD, a postdoctoral researcher in the Cancer Nanomedicine Lab at Memorial Sloan Kettering Cancer Center, was named to MIT Technology Review's 2022 Innovators Under 35 list in the…
Read More
March 17, 2022
Nanosensor Liquid Biopsy Detects Ovarian Cancer with 87% Sensitivity — Nature Biomedical Engineering
Nine Diagnostics Nanosensor Liquid Biopsy Detects Ovarian Cancer - Nature Biomedical Engineering
Mijin Kim, PhD, and Daniel A. Heller, PhD, at Memorial Sloan Kettering Cancer Center published a landmark study in Nature Biomedical Engineering (March 2022) demonstrating that quantum-defect-modified carbon nanotube nanosensor…
Read More
November 19, 2021
Nanosensor Liquid Biopsy to Detect Cancer Biomarkers — Science Advances
Science Advances - Nanosensor Liquid Biopsy to Detect Cancer Biomarkers
Daniel A. Heller, PhD, and colleagues at Memorial Sloan Kettering Cancer Center published a study in Science Advances (November 2021) introducing a perception-based nanosensor platform for detecting cancer biomarkers, demonstrating…
Read More
golden-ticket-16-9-low-res.png.corpimgo
MDSS_2
CancerHackerLab
Bright Edge Logo (PRNewsfoto/American Cancer Society)